TL;DR
Get pet supplies delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A randomized clinical trial of 168 dogs with Class 1 or 2 heartworm disease reported 95.3% efficacy for a two-dose melarsomine protocol and 98.8% for a three-dose protocol. All dogs survived treatment and complications were uncommon, but the findings apply to the studied treatment combination and disease classes; broader use and shelter-level effects remain to be established.
A randomized clinical trial found that a two-dose melarsomine protocol achieved 95.3% efficacy in 168 dogs with Class 1 or 2 heartworm disease, compared with 98.8% for a standard three-dose protocol. Published in the Journal of the American Veterinary Medical Association, the study also reported that all dogs survived treatment and complications were uncommon, findings that may matter to shelters managing treatment time and limited resources.
The study compared two melarsomine schedules alongside doxycycline, moxidectin and prednisone. Dogs in the compressed-protocol group received melarsomine injections on consecutive days 14 and 15. Dogs assigned to the three-dose group received injections on days 14, 44 and 45. Both groups were subject to four weeks of exercise restriction after treatment.
The reported efficacy was 95.3% for the two-dose regimen and 98.8% for the three-dose regimen. The source report does not provide further detail here on how efficacy was defined or the uncertainty around those estimates, so the percentages should be read as the trial’s reported results rather than a guarantee for an individual dog.
Complications were described as uncommon. Seven dogs required thoracic radiographs, with or without additional treatment, and none required intensive management. The trial ran from April 2024 through December 2025 and involved Lucky Dog Animal Rescue, the University of Florida Shelter Medicine Program, Toronto Humane Society and PetSmart Charities.
A Shorter Schedule for Shelters
The compressed schedule may reduce the time and resources needed to complete heartworm treatment, according to the report. For shelters facing crowding and budget constraints, a shorter course could make it easier to plan care and potentially increase the number of heartworm-positive dogs treated. Those are possible practical benefits, not outcomes directly established by the efficacy figures alone.
Keeping the comparison in view matters: the two-dose group’s reported efficacy was lower than the three-dose group’s, at 95.3% versus 98.8%. Shelters and veterinary teams weighing the approach will need to consider the trial’s full findings, individual animals’ needs and available veterinary guidance, rather than treating a shorter schedule as automatically suitable for every dog.
Products Worth Considering
PetSafe Electronic Pet Door – Collar Key Sensor – Large (up to 100 lb)
PETLIBRO Granary 2 Wi-Fi Automatic Pet Feeder with Smart Scale, 5L
PETLIBRO RFID Automatic Cat Feeder with Collar Sensor
As an affiliate, we earn on qualifying purchases.
How the Trial Compared Schedules
The study focused on dogs with Class 1 or 2 heartworm disease and compared two melarsomine schedules used with the same accompanying medications. The compressed course placed its two injections on consecutive days 14 and 15; the standard course spaced the second and third injections across days 44 and 45. Both groups had the same reported post-treatment exercise restriction.
The report describes the findings as supporting the safety and effectiveness of the two-dose approach when used with doxycycline, moxidectin and prednisone. Its conclusions are specific to this combination and the dogs included in the trial; the provided report does not establish results for other disease classes or different treatment protocols.
Limits of the Reported Results
The supplied report does not specify the trial’s detailed efficacy criteria, confidence intervals, or how results varied by participating site. It also does not say whether the study found a statistically significant difference between the two reported efficacy percentages. The numerical gap should not be interpreted as proof of equivalence or of a clinically meaningful difference without those details.
The trial covered 168 dogs with Class 1 or 2 disease. It is not clear from the report how well the results apply to dogs with more advanced disease, other health conditions, or settings outside the participating organizations. Nor does the summary quantify the claimed reductions in cost, staffing needs or treatment capacity for shelters.
Full Data and Veterinary Decisions
The next step for readers and veterinary teams is to consult the full JAVMA study for its methods, outcome definitions and statistical analysis. The source material does not identify a planned follow-up study, regulatory change or implementation date for shelters.
For now, the findings provide comparative trial evidence for a shorter regimen in the studied dogs, not a universal treatment instruction. Shelter staff should discuss protocol choices with veterinarians, who can assess the individual dog and the complete research evidence.
Key Questions
What did the two-dose heartworm protocol involve?
Dogs received melarsomine injections on days 14 and 15, alongside doxycycline, moxidectin and prednisone. The trial also required four weeks of exercise restriction after treatment.
How did its reported efficacy compare with three doses?
The trial reported 95.3% efficacy for the two-dose protocol and 98.8% for the three-dose protocol. The supplied report does not provide the statistical details needed to interpret whether that difference was significant.
Were there serious complications in the trial?
All dogs survived treatment, and complications were described as uncommon. Seven dogs needed chest radiographs, with or without additional treatment; none required intensive management.
Does the result apply to every dog with heartworm disease?
The trial included dogs with Class 1 or 2 disease. The report does not establish that the same results apply to more advanced disease or every clinical situation. Treatment decisions should be made with a veterinarian.
Source: veterinarypracticenews.com
